Consequently, the targeted modulation of BIRC3 gene expression and ubiquitination processes in TNFR1 or TRAIL signaling mediated by BIRC3 (cIAP2) present promising strategies for enhancing treatments for related disorders, including autoimmune diseases. Here, TNFRSF1A is linked to autoimmune disease.